Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Dec;176(12):1672-1673.
doi: 10.7326/M23-2887. Epub 2023 Nov 14.

Rebound of COVID-19 With Nirmatrelvir-Ritonavir Antiviral Therapy

Myron S Cohen  1 , Elizabeth R Brown  2
Affiliations
Editorial

Rebound of COVID-19 With Nirmatrelvir-Ritonavir Antiviral Therapy

Myron S Cohen et al. Ann Intern Med. 2023 Dec.

Abstract

In their article, Edelstein and colleagues provide the results of an observational study of virologic response in patients who received treatment with nirmatrelvir–ritonavir (N-R) versus those who received no COVID-19 therapy. The editorialists discuss the findings and emphasize the need for further consideration of the dosage, timing, and duration of treatment to inform optimal use of N-R.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M23-2887.

Comment on

  • SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study.
    Edelstein GE, Boucau J, Uddin R, Marino C, Liew MY, Barry M, Choudhary MC, Gilbert RF, Reynolds Z, Li Y, Tien D, Sagar S, Vyas TD, Kawano Y, Sparks JA, Hammond SP, Wallace Z, Vyas JM, Barczak AK, Lemieux JE, Li JZ, Siedner MJ. Edelstein GE, et al. Ann Intern Med. 2023 Dec;176(12):1577-1585. doi: 10.7326/M23-1756. Epub 2023 Nov 14. Ann Intern Med. 2023. PMID: 37956428 Free PMC article.

References

    1. Weinreich DM, Sivapalasingam S, Norton T, et al; Trial Investigators. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384:238-251. [PMID: ] doi:10.1056/NEJMoa2035002 - DOI - PMC - PubMed
    1. Hammond J, Leister-Tebbe H, Gardner A, et al; EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386:1397-1408. [PMID: ] doi:10.1056/NEJMoa2118542 - DOI - PMC - PubMed
    1. Arbel R, Wolff Sagy Y, Hoshen M, et al. Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge. N Engl J Med. 2022;387:790-798. [PMID: ] doi:10.1056/NEJMoa2204919 - DOI - PMC - PubMed
    1. Rubin R. From positive to negative to positive again—the mystery of why COVID-19 rebounds in some patients who take Paxlovid. JAMA. 2022;327:2380-2382. [PMID: ] doi:10.1001/jama.2022.9925 - DOI - PubMed
    1. Edelstein GE, Boucau J, Uddin R, et al. SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy. An observational study. Ann Intern Med. 2023. [Epub ahead of print]. doi:10.7326/M23-1756 - DOI - PMC - PubMed